Explore

Department of Health and Human Services Launches Genesis Mission to Advance AI in Biomedical Research

Department of Health and Human Services Launches Genesis Mission to Advance AI in Biomedical Research

The Department of Health and Human Services (HHS), in collaboration with the White House Office of Science and Technology Policy, has announced the Genesis Mission, a national initiative aimed at leveraging artificial intelligence and advanced computing to accelerate biomedical research. This mission is part of a broader effort to secure U.S. leadership in key technologies over the coming decade. The National Institutes of Health (NIH) is spearheading the Bio Genesis Mission, which focuses on using AI to address complex biological challenges, such as predicting living systems and accelerating drug discovery. The initiative also aims to improve health outcomes by fostering public-private partnerships and innovative policy approaches.

Biotech Innovations: Multiomics and Human Cell-Based Research Advancements

Biotech Innovations: Multiomics and Human Cell-Based Research Advancements

Biotech Innovations: Multiomics and Human Cell-Based Research Advancements

Nona Biosciences Partners with Medical University of Vienna for Antibody Development

Nona Biosciences Partners with Medical University of Vienna for Antibody Development

Nona Biosciences Partners with Medical University of Vienna for Antibody Development

Researchers Develop Patient-Derived Tumor Organoids to Enhance Cancer Treatment Personalization

Researchers Develop Patient-Derived Tumor Organoids to Enhance Cancer Treatment Personalization

Researchers have developed a pan-cancer patient-derived organoid (PDO) platform, consisting of 220 PDOs from 191 patients across 15 cancer types. This advancement is published in Science Advances and highlights the potential of tumor organoids as models for evaluating and optimizing cancer treatments. The organoids retain key characteristics of the parent tumors, showing high fidelity in histopathology, genomic concordance, and gene expression. This development allows for long-term screening and identification of unrecognized treatment candidates. The organoids have shown promise in screens to identify drugs that synergistically enhance the effects of existing treatments, such as PARP inhibitors. This approach could expand clinical criteria and improve treatment options for patients previously deemed ineligible for certain therapies.

Mount Sinai Researchers Uncover Structure of Brain Protein, Opening New Avenues for Epilepsy Treatment

Mount Sinai Researchers Uncover Structure of Brain Protein, Opening New Avenues for Epilepsy Treatment

Scientists at the Icahn School of Medicine at Mount Sinai have achieved a breakthrough in neurological research by revealing the high-resolution structure of NBCn2, a brain protein associated with epilepsy and other neurological disorders. Using cryo-electron microscopy, the team captured detailed images of NBCn2, which regulates acid-base balance in brain cells. This discovery has led to the development of the first compounds capable of inhibiting NBCn2's activity, potentially paving the way for new treatments for neurological conditions. The study, published in Nature Communications, highlights the protein's role in transporting sodium and carbonate ions to control brain cell activity. Researchers used the structural data to design compounds that reduced electrical signaling between neurons in experiments with mouse brain tissue.

Cold Spring Harbor Laboratory Scientists Revive Vancomycin to Combat Superbugs

Cold Spring Harbor Laboratory Scientists Revive Vancomycin to Combat Superbugs

Researchers at Cold Spring Harbor Laboratory (CSHL), led by Professor John Moses, have developed a method to restore the effectiveness of vancomycin, a powerful antibiotic that had become less effective against certain drug-resistant bacteria. The team utilized a technique called diversity oriented clicking (DOC) to create a library of over 150 compounds. In collaboration with Scripps Research, they identified a small molecule, pghi-4, which inhibits a bacterial enzyme called secreted antigen A (SagA). This inhibition allows vancomycin to regain its ability to kill drug-resistant strains of E. faecium, a pathogen known for causing severe infections. The research highlights the potential of using existing drugs in combination with new molecules to combat antibiotic resistance.

UCSD and IGI Partner to Advance CRISPR Innovations in Health and Environment

UCSD and IGI Partner to Advance CRISPR Innovations in Health and Environment

The University of California, San Diego (UCSD) has joined forces with the Innovative Genomics Institute (IGI) to enhance CRISPR technology applications in health and environmental sectors. Founded by Nobel laureate Jennifer Doudna, the IGI aims to translate gene editing successes into practical solutions for societal challenges. This partnership marks UCSD as the fourth UC partner, joining UC Berkeley, UC San Francisco, and UC Davis. The collaboration focuses on developing genome-editing tools to address issues like antibiotic-resistant infections and climate change. UCSD's strengths in environmental and marine sciences, engineering, and biomedical research complement IGI's mission to create scalable and accessible solutions.

US to spend $5 billion on health, construction research powered by AI

US to spend $5 billion on health, construction research powered by AI

By Courtney Rozen WASHINGTON, July 22 (Reuters) - The U.S. will spend $5 billion to tackle long-standing scientific problems across multiple fields using AI, the Trump administration said in a statement on Wednesday.

Challenges in Drug Discovery Highlight Need for Human-Centric Preclinical Models

Challenges in Drug Discovery Highlight Need for Human-Centric Preclinical Models

Challenges in Drug Discovery Highlight Need for Human-Centric Preclinical Models

Researchers Map Influenza Virus's Rewiring of Human Host Cells

Researchers Map Influenza Virus's Rewiring of Human Host Cells

Scientists at EMBL Hamburg and the Leibniz Research Institute for Molecular Pharmacology have mapped how the influenza A virus rewires human host cells. Using a specialized experimental workflow, they observed protein interactions within infected cells, providing unprecedented detail on how the virus manipulates host cell machinery. This research aims to enhance understanding of viral strategies, potentially leading to improved drug therapies and vaccines. The study marks the first time direct virus-host protein contacts have been mapped at scale within intact infected cells, offering insights into the virus's ability to hijack cellular processes.

Bristol Myers Squibb Partners with NVIDIA to Build Advanced AI Supercomputer for Drug Discovery

Bristol Myers Squibb Partners with NVIDIA to Build Advanced AI Supercomputer for Drug Discovery

Bristol Myers Squibb Partners with NVIDIA to Build Advanced AI Supercomputer for Drug Discovery

IntraBio's Research Reveals Levacetylleucine's Bidirectional Effect on Lysosomal Function

IntraBio's Research Reveals Levacetylleucine's Bidirectional Effect on Lysosomal Function

IntraBio has announced new research findings published in PLOS ONE, highlighting the bidirectional effect of levacetylleucine on lysosomal function. Conducted by researchers at the University of Oxford, the study reveals that levacetylleucine, the active ingredient in AQNEURSA, directly influences Transcription Factor EB (TFEB), a key regulator of lysosomal biogenesis and autophagy. The research identifies a unique biphasic action where levacetylleucine normalizes TFEB activity, activating it in deficient models and downregulating it when overstimulated, thus maintaining cellular homeostasis. This stereospecific effect is rapid, occurring within an hour, and is exclusive to the L-enantiomer of levacetylleucine.